- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04491526
Study to Prevent Postoperative Urinary Retention (STOP-POUR)
Randomized, Quadruple Blinded, Placebo Controlled, Multi-centered Trial Investigating Prophylactic Tamsulosin in Prevention of Postoperative Urinary Retention in Men After Endoscopic Total Extraperitoneal Inguinal Hernia Repair
Post-operative urinary retention (POUR) is a common complication after inguinal hernia repair with a reported incidence up 34%. It can be described as the inability to initiate urination or properly empty one's bladder following surgery. It is usually self-limited, but it requires the use of catheterization to empty the bladder in order to prevent further injury to the bladder or kidneys and to relief the discomfort of a full bladder. Tamsulosin is a medication that is commonly used in men with urinary symptoms related to an enlarged prostate. There is some evidence to suggest that it may also potentially be beneficial for preventing post-operative urinary retention.
The purpose of this study is to determine if tamsulosin ("TAMSULOSIN Mepha Ret Depocaps 0.4 mg") is effective in preventing post-operative urinary retention following endoscopic total extraperitoneal inguinal hernia repair and its impact on hospital length of stay.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Uwe Bieri, MD
- Phone Number: +4179 268 78 37
- Email: uwe.bieri@gmail.com
Study Contact Backup
- Name: Juliette Slieker, MD
- Phone Number: +41 (056) 486 10 20
- Email: Juliette.Slieker@ksb.ch
Study Locations
-
-
Aargau
-
Baden, Aargau, Switzerland, 5404
- Recruiting
- Kantonsspital Baden
-
Contact:
- Juliette Slieker, MD
- Phone Number: +41 56 486 10 20
- Email: juliette.slieker@ksb.ch
-
Contact:
- Uwe Bieri, MD
- Phone Number: +41792687837
- Email: uwe.bieri@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males
- ≥60 years old
- Planned uni- or bilateral endoscopic total extraperitoneal inguinal hernia repair
- Surgery scheduled more than 6 days from the time of consent
- Informed Consent as documented by signature (Appendix Informed Consent Form)
Exclusion Criteria:
- Orthostatic hypotension (feeling of dizziness after getting up from a sitting or lying position)
- Severe liver disease (Child Pugh C)
- Taking strong inhibitors of CYP3A4 (ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir/ritonavir, lopinavir, or conivaptan)
- Being on alpha-blockers (alfuzosin, doxazosin, prazosin, terazosin, tamsulosin, phenoxybenzamine, or silodosin) or a combination product containing alpha-blocker (duodart)
- History of allergy or sensitivity to tamsulosin or other alpha-blockers (alfuzosin, doxazosin, prazosin, terazosin, or phenoxybenzamine)
- Long term Indwelling urinary or suprapubic catheter
- Status post cystectomy
- Inability to provide informed consent
- Known or suspected non-compliance, drug or alcohol abuse,
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
- Participation in another study with investigational drug within the 30 days preceding and during the present study,
- Previous enrolment into the current study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tamsulosin Arm
p.o.
|
0.4mg/day Tamsulosin hydrochloride ("TAMSULOSIN Mepha Ret Depocaps 0.4 mg") from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery.
(5+1+1)
Other Names:
|
Placebo Comparator: Placebo Arm
p.o.
|
One placebo capsule matching the active study drug per day from 5 days prior to the day of surgery, at the day of surgery and for 1 day following surgery.
(5+1+1)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post operative urinary retention (Need for any catheterization postoperatively)
Time Frame: up to 3 days after surgery
|
Need for any catheterization postoperatively (Yes/No)
|
up to 3 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first voiding after surgery
Time Frame: up to 3 days after surgery
|
secondary outcomes in Non-POUR Patients
|
up to 3 days after surgery
|
Urinary Volume measurement at defined points in time (n)
Time Frame: up to 12 hours after surgery
|
secondary outcomes in all Patients
|
up to 12 hours after surgery
|
Volume of first micturition after surgery
Time Frame: up to 12 hours after surgery
|
secondary outcomes in Non-POUR Patients
|
up to 12 hours after surgery
|
Post-operative Pain (Quantity of Pain / VAS-Score)
Time Frame: up to 3 days after surgery
|
Quantity of pain is verified at arrival in the PACU and at every 6 hours by the nursing staff, using the standardised numeric rating scale.
The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain.
It is for adults and children 10 years old or older.
|
up to 3 days after surgery
|
Need for opioid analgesics post operatively
Time Frame: up to 3 days after surgery
|
secondary outcomes in all Patients
|
up to 3 days after surgery
|
Quantity of post-operative opioid use (opioid dosage will be converted to oral morphine equivalence dose)
Time Frame: up to 3 days after surgery
|
opioid use is documented in the patient's record, opioid dosage will be converted to oral morphine equivalence dose
|
up to 3 days after surgery
|
Intraoperative applications of opioid analgesics (Yes/No)
Time Frame: intra-operative period
|
Opioid use during surgery is documented in the patient's record, this is a binary endpoint opioid use; (yes/ no)
|
intra-operative period
|
Quantity of intra-operative opioid use opioid dosage will be converted to oral morphine equivalence dose)
Time Frame: intra-operative period
|
Opioid use during surgery is documented in the patient's record, opioid dosage will be converted to oral morphine equivalence dose
|
intra-operative period
|
Amount of intraoperative fluid administration
Time Frame: intra-operative period
|
Intraoperative fluid administration (in milliliter) is documented in the patient's record
|
intra-operative period
|
International Prostate Symptom Score (IPSS score) pre-surgery (-5d)
Time Frame: min. 5 days prior to surgery
|
0-7 Mildly symptomatic / 8-19 Moderately symptomatic / 20-35 Severely symptomatic
|
min. 5 days prior to surgery
|
International Prostate Symptom Score (IPSS score) post-surgery (3d)
Time Frame: 3 days post surgery
|
0-7 Mildly symptomatic / 8-19 Moderately symptomatic / 20-35 Severely symptomatic
|
3 days post surgery
|
Change in International Prostate Symptom Score (IPSS score) from baseline prior to surgery (-5d) to day 3(+3d) after surgery
Time Frame: 3 days post surgery
|
0-7 Mildly symptomatic / 8-19 Moderately symptomatic / 20-35 Severely symptomatic
|
3 days post surgery
|
Side-effects of study medication (orthostatic hypotension, retrograde ejaculation, Floppy-Iris-Syndrom)
Time Frame: 5 days prior to surgery (-5d) to day 3(+3d) after surgery
|
Will be documented in the patient record by the study personnel, binary endpoint (Yes/No)
|
5 days prior to surgery (-5d) to day 3(+3d) after surgery
|
In hospital complications (using the evaluated standard classification for complication in surgery (Classification Grade I-V) )
Time Frame: as long as the patient is labeled inpatient, on average 1-3 days
|
secondary outcomes in all Patients
|
as long as the patient is labeled inpatient, on average 1-3 days
|
Length of hospital stay in days (Inpatients)
Time Frame: as long as the patient is labeled inpatient, on average 1-3 days
|
secondary outcomes in all Patients
|
as long as the patient is labeled inpatient, on average 1-3 days
|
Time to discharge after surgery in hours (outpatients)
Time Frame: up to 12 hours after surgery
|
secondary outcomes in all Patients
|
up to 12 hours after surgery
|
Residual urinary volume after catherization
Time Frame: up to 12 hours after surgery
|
secondary outcomes in POUR Patients
|
up to 12 hours after surgery
|
Macrohematuria
Time Frame: 3 days post surgery
|
secondary outcomes in POUR Patients
|
3 days post surgery
|
Relevant injury to the urethra (Presence of a Via falsa diagnosed by a urologist)
Time Frame: 3 days post surgery
|
secondary outcomes in POUR Patients
|
3 days post surgery
|
Catheter-related infections
Time Frame: 3 days post surgery
|
secondary outcomes in POUR Patients
|
3 days post surgery
|
Catheter-related bladder discomfort ( (Ggrading according to the 3three Ggrades (mild, moderate, severe)
Time Frame: 3 days post surgery
|
secondary outcomes in POUR Patients
|
3 days post surgery
|
Prostatitis
Time Frame: 3 days post surgery
|
secondary outcomes in POUR Patients
|
3 days post surgery
|
Failed first trial without catheter (TWOC: need for a second catheter insertion due to insufficient voiding after TWOC).
Time Frame: 1 day post surgery
|
secondary outcomes in POUR Patients
|
1 day post surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Antonio Nocito, Prof, Kantonsspital Baden AG, Im Ergel 1, 5404 Baden, Switzerland
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Urination Disorders
- Pathological Conditions, Anatomical
- Hernia, Abdominal
- Hernia
- Hernia, Inguinal
- Urinary Retention
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Tamsulosin
Other Study ID Numbers
- 2020-00569
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inguinal Hernia
-
Children's Mercy Hospital Kansas CityRecruitingInguinal Hernia | Inguinal Hernia, Indirect | Inguinal Hernia Unilateral | Inguinal Hernia BilateralUnited States
-
Hospital General Universitario ElcheCompletedInguinal Hernia | Inguinal Hernia Repair | Open Inguinal Hernia
-
San Bonifacio HospitalCompletedIndirect Inguinal Hernia | Direct Inguinal HerniaItaly
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalEnrolling by invitationInguinal Hernia | Strangulated Inguinal Hernia | Incarcerated Inguinal HerniaTurkey
-
University Hospital, GhentMedriCompleted
-
Ahmadullah DanishCompletedIncarcerated Inguinal HerniaAfghanistan
-
General Hospital of LarissaUnknown
-
Alexandria UniversityCompletedBilateral Inguinal Hernia
-
Hospital Siberia-SerenaUnknownPrimary Inguinal HerniaSpain
-
Diskapi Teaching and Research HospitalCompleted
Clinical Trials on TAMSULOSIN Mepha Ret Depocaps 0.4 mg
-
Astellas Pharma Europe B.V.CompletedLower Urinary Tract Symptoms | Benign Prostatic HyperplasiaBelgium, Italy, France, Austria, United Kingdom, Netherlands, Hungary, Russian Federation, Poland, Slovakia, Czech Republic, Belarus, Germany
-
Azienda Ospedaliero Universitaria Maggiore della...RecruitingLower Urinary Tract Symptoms | Benign Prostatic Hyperplasia | Urinary ObstructionItaly
-
Mansoura UniversityActive, not recruitingOveractive Bladder | Benign Prostatic HyperplasiaEgypt
-
Astellas Pharma Europe B.V.CompletedLower Urinary Tract Symptoms | Benign Prostatic HyperplasiaBelgium, Italy, France, Austria, United Kingdom, Netherlands, Poland, Slovakia, Belarus, Germany, Czechia
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedUrologic DiseasesUnited Kingdom
-
GlaxoSmithKlineCompletedUrologic DiseasesUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisTerminated
-
Kocatepe UniversityCompletedBenign Prostatic Hyperplasia | Choroid Disease | Pupil Anomaly
-
ChaingMai UniversityUnknown